Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07501039

A Phase 1 Study of BLKR201 in Healthy Adult Participants

The goal of this clinical trial is to learn if BLKR201 is safe in healthy adults. Researchers will also learn how the body absorbs and processes BLKR201 and how food may affect it.

The main questions this study aims to answer are:

* Is BLKR201 safe and well tolerated when taken as a single dose or for several days in a row? * How does BLKR201 move through and leave the body? * Does taking BLKR201 with food change how the body absorbs it?

Researchers will compare BLKR201 to a placebo (a look-alike tablet that contains no drug) in most parts of the study to see how the drug affects participants.

Participants will:

* Take BLKR201 or a placebo by mouth * Stay at a clinical research unit for several days during dosing * Give blood and urine samples * Have heart tests, vital signs, and lab tests * Report any side effects

In one part of the study, a small group of participants will receive BLKR201 only (no placebo). These participants will also have a sample of spinal fluid collected to measure how much BLKR201 reaches the fluid around the brain and spinal cord.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Healthy

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Are a healthy man or woman 18 to 55 years old
  • Weigh at least 50 kilograms (110 pounds)
  • Have a body mass index (BMI) between 18 and 30
  • Are willing to stay at the research unit for the required study visits
  • Are willing to follow study rules about diet, alcohol, tobacco, and medications
  • Are able to understand and sign the informed consent form

Women who can become pregnant must:

  • Have a negative pregnancy test before starting
  • Use a highly effective form of birth control during the study and for a period after the last dose

Men with partners who can become pregnant must:

  • Use highly effective birth control during the study and for a period after the last dose
  • Not donate sperm during that time

Exclusion criteria

  • Have any significant medical condition involving the heart, lungs, liver, kidneys, stomach, intestines, brain, blood, or immune system
  • Have abnormal laboratory test results at screening that the study doctor considers important
  • Have a history of heart rhythm problems or abnormal electrocardiogram (ECG) results
  • Have high blood pressure at screening
  • Have had a serious infection within the past 6 months
  • Test positive for HIV, hepatitis B, hepatitis C, or tuberculosis
  • Have a history of cancer in the past 5 years (with limited exceptions for certain treated skin cancers)
  • Have a history of serious stomach problems such as ulcers, stomach surgery, or stomach bleeding
  • Use tobacco, nicotine, or marijuana products
  • Test positive for drugs or alcohol at screening
  • Have taken another investigational drug within the required time before this study
  • Have received a live vaccine within 30 days before study start
  • Are pregnant or breastfeeding
  • Have a known allergy to the study drug or similar medicines

Additional exclusions:

  • Regular heavy alcohol use
  • Regular use of certain medications such as anti-inflammatory drugs, steroids, or blood thinners
  • Donation of more than 500 milliliters (about one pint) of blood within 1 month before screening

For the spinal fluid (CSF) portion of the study, you cannot take part if you:

  • Take blood-thinning medications
  • Have bleeding or clotting problems
  • Have medical conditions that make a spinal tap unsafe

Treatment and study plan

BLKR201

Drug

BLKR201 is administered orally as a single ascending dose in the SAD stage. In the food effect cohort, BLKR201 is administered under both fasted and fed conditions in separate periods.

Placebo

Drug

A matching placebo tablet administered orally, corresponding to the dose level and dosing condition of BLKR201 in each assigned cohort.

Primary outcomes

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Baseline through approximately 7 days after final dose

    Treatment-emergent adverse events are defined as adverse events that begin or worsen after administration of BLKR201 or placebo. Events will be summarized by frequency and severity.

  2. Change From Baseline in Clinical Laboratory Parameters

    Time frame: Baseline through approximately 7 days after final dose

    Clinical laboratory parameters include hematology, clinical chemistry, coagulation, lipid panel, and urinalysis. Change from baseline values will be summarized at scheduled post-dose assessments.

  3. Change From Baseline in Systolic Blood Pressure

    Time frame: Baseline through approximately 7 days after final dose

    Systolic blood pressure will be measured in millimeters of mercury (mmHg). Change from baseline will be summarized at scheduled post-dose assessments.

  4. Change From Baseline in Diastolic Blood Pressure

    Time frame: Baseline through approximately 7 days after final dose

    Diastolic blood pressure will be measured in millimeters of mercury (mmHg). Change from baseline will be summarized at scheduled post-dose assessments.

  5. Change From Baseline in Pulse Rate

    Time frame: Baseline through approximately 7 days after final dose

    Pulse rate will be measured in beats per minute (bpm). Change from baseline will be summarized at scheduled post-dose assessments.

  6. Change From Baseline in Respiratory Rate

    Time frame: Baseline through approximately 7 days after final dose

    Respiratory rate will be measured in breaths per minute. Change from baseline will be summarized at scheduled post-dose assessments.

  7. Change From Baseline in Body Temperature

    Time frame: Baseline through approximately 7 days after final dose

    Body temperature will be measured in degrees Fahrenheit (°F). Change from baseline will be summarized at scheduled post-dose assessments.

  8. Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters

    Time frame: Baseline through approximately 7 days after final dose

    ECG parameters include QT interval corrected using Fridericia's formula (QTcF), PR interval, QRS duration, and heart rate. Change from baseline values will be summarized at scheduled post-dose assessments.

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of BLKR201 After Single Oral Dose

    Time frame: From predose through approximately 7 days after final dose

    Cmax is the highest measured plasma concentration of BLKR201 following a single oral dose.

  2. Area Under the Plasma Concentration-Time Curve (AUC) of BLKR201 After Single Oral Dose

    Time frame: From predose through approximately 7 days after final dose

    Area under the plasma concentration-time curve (AUClast and AUCinf) will be calculated using non-compartmental analysis to describe overall drug exposure.

  3. Maximum Observed Plasma Concentration (Cmax) After Multiple Doses

    Time frame: From predose through approximately 7 days after final dose

    Cmax at steady state will be calculated after repeated daily dosing.

  4. Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUCtau) After Multiple Doses

    Time frame: From predose through approximately 7 days after final dose

    AUCtau will be calculated to describe total drug exposure during a dosing interval after repeated dosing.

  5. BLKR201 Concentration in Cerebrospinal Fluid (CSF)

    Time frame: Day 7 post-dose in the CSF cohort (single CSF sampling time point per participant)

    BLKR201 concentrations will be measured in cerebrospinal fluid to assess central nervous system exposure.

  6. Amount of BLKR201 Excreted in Urine

    Time frame: From predose through 48 hours post-dose (in certain SAD cohorts only)

    The amount of BLKR201 excreted in urine will be calculated over defined collection intervals.

  7. Ratio of Maximum Observed Plasma Concentration (Cmax) of BLKR201 Under Fed Versus Fasted Conditions

    Time frame: From predose through 48 hours post-dose (in certain SAD cohorts only)

    The ratio of Cmax under fed and fasted conditions will be calculated to evaluate the effect of a high-fat meal on BLKR201 exposure.

  8. Ratio of Area Under the Plasma Concentration Versus Time Curve (AUC) of BLKR201 Under Fed Versus Fasted Conditions

    Time frame: From predose through 48 hours post-dose (in certain SAD cohorts only)

    The ratio of AUC under fed and fasted conditions will be calculated to evaluate the effect of a high-fat meal on BLKR201 exposure.

Sponsors and collaborators

Lead sponsor

Formation Bio, Inc.

Industry

Registry information

Official study title

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BLKR201 in Healthy Adult Participants

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Mar 30, 2026
Registry last updated
Apr 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.